More medical options for every family

The umbilical cord comprises Wharton's jelly, umbilical arteries and an umbilical vein. These components are protected by a sheet-like membrane known as cord lining. Wharton's jelly contains Mesenchymal stem cells ("MSCs"), while cord lining contains both MSCs and Epithelial stem cells ("EpSCs"). Both types of stem cells are currently being evaluated in more than 400 clinical trials for medical conditions such as heart disease, stroke, spinal cord injury, corneal repair, and even wounds from burns and diabetic ulcers. As stem cells are capable of immune system modulation, a donor’s cells need not be an exact match for the patient’s, making these cells potentially useful for the whole family.

Cord lining banking is a patented technology made available to all Cordlife clients in Asia through an exclusive licensing agreement with Cordlabs, a subsidiary of CellResearch Corporation ("CRC"). CRC was founded by a team of Singapore experts, including an award-winning doctor and a scientist who both made significant inroads into the medical world with their discovery of stem cells from cord lining. CRC has secured patent protection for cord lining banking in 40 territories worldwide, preventing other companies from harvesting stem cells from cord lining without licensing the technology from them.

Cordlife also offers cord tissue banking as a lower-cost alternative to cord lining banking.